The text starts here.

News Release

FOR IMMEDIATE RELEASE
June 15, 1998

Eisai Launches Myocardial Infarction Treatment "CLEACTOR"

Tokyo (June 15, 1998) - Eisai Co., Ltd. of Tokyo (President and CEO:Haruo Naito) today announced the launch of a thrombolytic for treatment of acute myocardial infarction, CLEACTOR, (generic name: monteplaser (DNA origin)).


CLEACTOR, a new generation thrombolytic, was independently developed by Eisai utilizing recombinant DNA techniques. The administration of native t-PA (tissue-type plasminogen activator) via intravenous infusion takes longer than one hour; however, the administration of CLEACTOR, when given as a bolus injection, is achieved in about two minutes with an elimination of half-life in blood plasma of greater than 20 minutes.


In clinical trials CLEACTOR promoted a high percentage of recanalization of coronary arteries at an earlier time compared to native t-PA, this efficacy is reflected in CLEACTOR's NHI drug price supplemental classification II.


In the treatment for acute myocardial infarction, or heart attack, it is extremely important to resume blood flow as quickly as possible to limit the area of damage to the heart muscle and improve recovery prognosis. CLEACTOR, when given as a bolus injection, demonstrates a high ease of usage and effectiveness.


In Japan the number of people having acute myocardial infarction is estimated to be 100,000 to 150,000 a year. The t-PA market in Japan is estimated to be approximately yen4 billion yen. The sales objective for CLEACTOR in fiscal year 1998 is yen1.5 billion yen.


CLEACTOR is indicated for acute coronary infarction treatment and on March 20, 1998, a classification as an orphan for the indication of "lysis of thromboemboli in the pulmonary arteries in patients with acute pulmonary embolism" was granted. In the future Phase III clinical trials are planned.


Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. The company reported sales of about $2.3 billion in 1997 with approximately 16 percent of sales spent for research and development.


CLEACTOR is a trademark of Eisai Co., Ltd.